The wider perspective: cord blood banks and their future prospects.
Adult
Allografts
Blood Banks
/ organization & administration
Blood Preservation
/ methods
Cord Blood Stem Cell Transplantation
Cryopreservation
/ methods
Fetal Blood
Forecasting
Graft vs Leukemia Effect
Humans
Immunotherapy, Adoptive
Infant, Newborn
Precision Medicine
Quality Assurance, Health Care
Regenerative Medicine
Tissue and Organ Harvesting
Transfusion Medicine
Treatment Outcome
CB banks
cell and advanced therapies
cryopreserved cord blood
haematopoietic progenitor cell transplantation
specialised transfusion
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
pubmed:
21
4
2021
medline:
24
12
2021
entrez:
20
4
2021
Statut:
ppublish
Résumé
Over the past three decades, cord blood transplantation (CBT) has established its role as an alternative allograft stem cell source. But the future of stored CB units should be to extend their use in updated transplant approaches and develop new CB applications. Thus, CBT will require a coordinated, multicentric, review of transplantation methods and an upgrade and realignment of banking resources and operations. Significant improvements have already been proposed to support the clinical perspective including definition of the cellular threshold for engraftment, development of transplantation methods for adult patients, engraftment acceleration with single cell expansion and homing technologies, personalised protocols to improve efficacy, use of adoptive cell therapy to mitigate delayed immune reconstitution, and further enhancement of the graft-versus-leukaemia effect using advanced therapies. The role of CB banks in improving transplantation results are also critical by optimizing the collection, processing, storage and characterization of CB units, and improving reproducibility, efficiency and cost of banking. But future developments beyond transplantation are needed. This implies the extension from transplantation banks to banks that support cell therapy, regenerative medicine and specialized transfusion medicine. This new "CB banking 2.0" concept will require promotion of international scientific and technical collaborations between bank specialists, clinical investigators and transplant physicians.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-517Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Kindwall-Keller TL, Ballen KK. Alternative donor graft sources for adults with hematologic malignancies: a donor for all patients in 2017!. Oncologist. 2017;22:1125-34.
Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137:420-8.
Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020;4:2227-35.
Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. Haematologica. 2020;105:2716-29.
Scaradavou A. Cord blood beyond transplantation: can we use the experience to advance all cell therapies? Br J Haematol. 2021. https://doi.org/10.1111/bjh.17297.
Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010;16:1541-8.
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339-48.
Dessels C, Alessandrini M, Pepper MS. Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape. Stem Cells Transl Med. 2018;7:643-50.
Ballen K. Update on umbilical cord blood transplantation. F1000Res. 2017;6:1556.
Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147:262-74.
Politikos I, Davis E, Nhaissi M, Wagner JE, Brunstein CG, Cohen S, et al. Guidelines for cord blood unit selection. Biol Blood Marrow Transplant. 2020;26:2190-6.
Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, DeFor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116:4693-9.
Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133-40.
Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, et al. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017;4:e325-33.
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944-53.
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891-900.
Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, et al. Comparison of graft acquisition and early direct charges of haploidentical related donor transplantation versus umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2019;25:1456-64.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplantation for pediatric leukemia: a merged center for international blood and marrow transplant research and pediatric health information system analysis. Biol Blood Marrow Transplant. 2020;26:1747-56.
Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood Am Soc Hematol. 2019;134:924-34.
Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L, et al. Impact of selection of cord blood units from the United States and Swiss registries on the cost of banking operations. Transfus Med Hemother. 2013;40:14-20.
Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343-7.
Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H, et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1316-26.
Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121:752-8.
Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, et al. High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2015;21:1985-93.
Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2013;19:799-803.
Magro E, Regidor C, Cabrera R, Sanjuán I, Forès R, Garcia-Marco JA, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica. 2006;91:640-8.
van Besien K, Hari P, Zhang M-J, Liu H-T, Stock W, Godley L, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016;101:634-43.
Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019;37:367-74.
Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16:232-6.
de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367:2305-15.
Wagner J, Brunstein C, Boitano A, DeFor T, McKenna D, Sumstad D, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016;18:144-55.
Stiff PJ, Montesinos P, Peled T, Landau E, Goudsmid NR, Mandel J, et al. Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biol Blood Marrow Transplant. 2018;24:1463-70.
Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020;7:e134-e145.
Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122:3074-81.
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015;125:2885-92.
Farag SS, Nelson R, Cairo MS, O'Leary HA, Zhang S, Huntley C, et al. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. Oncotarget. 2017;8:110350-7.
Broxmeyer HE. Long-overdue guidelines for the cord blood banking community. Stem Cells Transl Med. 2019;8:320-2.
Milano F, Gutman JA, Deeg HJ, Nemecek ER, Baumgart J, Thur L, et al. Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. Blood Adv. 2020;4:3302-10.
Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016;128:2734-41.
Thus KA, de Hoop TA, de Weger RA, Bierings MB, Boelens JJ, Spierings E, et al. Predicted indirectly recognizable HLA epitopes class I promote antileukemia responses after cord blood transplantation: indications for a potential novel donor selection tool. Biol Blood Marrow Transplant. 2016;22:170-3.
Petersdorf EW, Gooley T, Volt F, Kenzey C, Madrigal A, McKallor C, et al. Use of the HLA-B leader to optimize cord-blood transplantation. Haematologica. 2020. https://doi.org/10.3324/haematol.2020.264424.
Kanda J, Kawase T, Tanaka H, Kojima H, Morishima Y, Uchida N, et al. Effects of haplotype matching on outcomes after adult single-cord blood transplantation. Biol Blood Marrow Transplant. 2020;26:509-18.
Politikos I, Lavery JA, Hilden P, Cho C, Borrill T, Maloy MA, et al. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. Blood Adv. 2020;4:191-202.
Abraham AA, John TD, Keller MD, Cruz CRY, Salem B, Roesch L, et al. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019;3:2057-68.
Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010;115:757-65.
Hiwarkar P, Adams S, Gilmour K, Nataraj R, Bonney D, Poulton K, et al. Cord blood CD8+ T-cell expansion following granulocyte transfusions eradicates refractory leukemia. Blood Adv. 2020;4:4165-74.
de Haar C, Plantinga M, Blokland NJG, van Til NP, Flinsenberg TWH, Van Tendeloo VF, et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology. 2015;4:1-11.
Plantinga M, Lo Presti V, de Haar CG, Dünnebach E, Madrigal A, Lindemans CA, et al. Clinical grade production of Wilms' tumor-1 loaded cord blood-derived dendritic cells to prevent relapse in pediatric AML after cord blood transplantation. Front Immunol. 2020;11:559152.
Wagner E, Duval M, Dalle J-H, Morin H, Bizier S, Champagne J, et al. Assessment of cord blood unit characteristics on the day of transplant: comparison with data issued by cord blood banks. Transfusion. 2006;46:1190-8.
Querol S, Gomez SG, Pagliuca A, Torrabadella M, Madrigal JA. Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplant. 2010;45:970-8.
Fry LJ, Giner SQ, Gomez SG, Green M, Anderson S, Horder J, et al. Avoiding room temperature storage and delayed cryopreservation provide better postthaw potency in hematopoietic progenitor cell grafts. Transfusion. 2013;53:1834-42.
Lin X, Torrabadella M, Amat L, Gómez S, Azqueta C, Sánchez M, et al. Estimated fetal weight percentile as a tool to predict collection of cord blood units with higher cellular content: implications for prenatal selection of cord blood donors. Transfusion. 2018;58:1732-8.
Askelöf U, Andersson O, Domellöf M, Fasth A, Hallberg B, Hellström-Westas L, et al. Wait a minute? An observational cohort study comparing iron stores in healthy Swedish infants at 4 months of age after 10-, 60- and 180-second umbilical cord clamping. BMJ Open. 2017;7:12.
Vanegas D, Triviño L, Galindo C, Franco L, Salguero G, Camacho B, et al. A new strategy for umbilical cord blood collection developed at the first Colombian public cord blood bank increases total nucleated cell content. Transfusion. 2017;57:2225-33.
Ciubotariu R, Scaradavou A, Ciubotariu I, Tarnawski M, Lloyd S, Albano M, et al. Impact of delayed umbilical cord clamping on public cord blood donations: can we help future patients and benefit infant donors? Transfusion. 2018;58:1427-33.
Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, et al. Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: a study of 2456 umbilical cord blood recipients. Biol Blood Marrow Transplant. 2020;26:745-57.
Urbansky A, Ohlsson P, Lenshof A, Garofalo F, Scheding S, Laurell T, et al. Rapid and effective enrichment of mononuclear cells from blood using acoustophoresis. Sci Rep. 2017;7:17161.
Choi S, Hoffmann S, Cooling L. Another case of acute cardiopulmonary toxicity with cord blood infusion: is dextran the culprit? Transfusion. 2012;52:207-8.
Solves P, Planelles D, Mirabet V, Blanquer A, Carbonell-Uberos F. Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus. 2013;11:405-11.
Pasha R, Howell A, Turner TR, Halpenny M, Elmoazzen H, Acker JP, et al. Transient warming affects potency of cryopreserved cord blood units. Cytotherapy. 2020;22:690-7.
Tokuno O, Hayakawa A, Yanai T, Mori T, Ohnuma K, Tani A, et al. Sterility testing of stem cell products by broad-range bacterial 16S ribosomal DNA polymerase chain reaction. Lab Med. 2015;46:34-41.
Takanashi M, Selogie E, Reems J-A, Stroncek D, Fontaine MJ, Girdlestone J, et al. Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion. 2018;58:2184-91.
Enrich E, Vidal F, Corrales I, Campos E, Borràs N, Martorell L, et al. Improving cord blood typing with next-generation sequencing: impact of allele-level HLA and NIMA determination on their selection for transplantation. Bone Marrow Transplant. 2020;55:1623-31.
Sekine T, Marin D, Cao K, Li LI, Mehta P, Shaim H, et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016;128:297-312.
Cunha R, Zago MA, Querol S, Volt F, Ruggeri A, Sanz G, et al. Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. Blood. 2017;129:525-32.
Fournier D, Lewin A, Simard C, Trépanier P, Néron S, Ballerini L, et al. Multi-laboratory assay for harmonization of enumeration of viable CD34+ and CD45+ cells in frozen cord blood units. Cytotherapy. 2020;22:44-51.
Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T, et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant. 2011;17:1362-74.
Castillo N, García-Cadenas I, Barba P, Martino R, Azqueta C, Ferrà C, et al. Post-Thaw viable CD45+ cells and clonogenic efficiency are associated with better engraftment and outcomes after single cord blood transplantation in adult patients with malignant diseases. Biol Blood Marrow Transplant. 2015;21:2167-72.
Duggleby RC, Querol S, Davy RC, Fry LJ, Gibson DA, Horton RBV, et al. Flow cytometry assessment of apoptotic CD34+ cells by annexin v labeling may improve prediction of cord blood potency for engraftment. Transfusion. 2012;52:549-59.
Shoulars K, Noldner P, Troy JD, Cheatham L, Parrish A, Page K, et al. Development and validation of a rapid, aldehyde dehydrogenase bright-based cord blood potency assay. Blood. 2016;127:2346-54.
Simard C, Bonnaure G, Fournier D, Néron S. An objective flow cytometry method to rapidly determine cord blood potency in cryopreserved units. Transfusion. 2019;59:2074-83.
Model criteria for regulation of cord blood banks and cord blood banking: adopted by the Cord Blood Association, Board of Directors, 2019. Stem Cells Transl Med. 2019;8:340-3.
Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020;55:2043-4.
Case C. 10 years of preparedness by the radiation injury treatment network. Curr Hematol Malignancy Rep. 2017;12:39-43.
Jöris M, Paulson K, Foley L, Duffy M, Querol S, Gomez S, et al. Worldwide survey on key indicators for public cord blood banking technologies: by the World Marrow Donor Association Cord Blood Working Group. Stem Cells Transl Med. 2020;10:222-9.
Magalon J, Maiers M, Kurtzberg J, Navarrete C, Rubinstein P, Brown C, et al. Banking or bankrupting: strategies for sustaining the economic future of public cord blood banks. PLoS One. 2015;10:e0143440.
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:882-96.
Querol S, Samarkanova D. Rapid review: next generation of cord blood banks; transplantation and beyond. Transfusion. 2019;59:3048-50.
Resnik DB. Re-consenting human subjects: ethical, legal and practical issues. J Med Ethics. 2009;35:656-7.
Alvarez-Palomo B, Vives J, Casaroli-Marano RP, G. Gomez SG, Rodriguez Gómez L, Edel M, et al. Adapting cord blood collection and banking standard operating procedures for HLA-homozygous induced pluripotent stem cells production and banking for clinical application. J Clin Med. 2019;8:476.
Dave H, Luo M, Blaney JW, Patel S, Barese C, Cruz CR, et al. Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood. Mol Ther Methods Clin Dev. 2017;5:13-21.
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity HHS Public Access. Leukemia. 2018;32:520-31.
Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2020;137:624-36.
Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, et al. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Cancer Sci. 2020;111:1478-90.
Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJN, et al. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014;16:90-100.
Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016;127:1044-51.
Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, et al. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018;9:35611-22.
Laskowitz DT, Bennett ER, Durham RJ, Volpi JJ, Wiese JR, Frankel M, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase 1 safety study. Stem Cells Transl Med. 2018;7:521-9.
Davies JE, Walker JT, Keating A. Concise review: Wharton's Jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Transl Med. 2017;6:1620-30.
Shivakumar SB, Bharti D, Subbarao RB, Jang S-J, Park J-S, Ullah I, et al. DMSO- and serum-free cryopreservation of Wharton's jelly tissue isolated from human umbilical cord. J Cell Biochem. 2016;117:2397-412.
Prat-Vidal C, Rodríguez-Gómez L, Aylagas M, Nieto-Nicolau N, Gastelurrutia P, Agustí E, et al. First-in-human PeriCord cardiac bioimplant: scalability and GMP manufacturing of an allogeneic engineered tissue graft. EBioMedicine. 2020;54:102729.
Stefańska K, Ożegowska K, Hutchings G, Popis M, Moncrieff L, Dompe C, et al. Human Wharton's Jelly - cellular specificity, stemness potency, animal models, and current application in human clinical trials. J Clin Med. 2020;9:1102.
Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, et al. Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl. Med. 2020;9:1007-22.
Reid E, Guduric-Fuchs J, O'Neill CL, Allen L-D, Chambers SEJ, Stitt AW, et al. Preclinical evaluation and optimization of a cell therapy using human cord blood-derived endothelial colony-forming cells for ischemic retinopathies. Stem Cells Transl Med. 2018;7:59-67.
Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008;26:739-40.
Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A, Belmonte JCI, et al. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and sox2. Nat Protoc. 2010;5:811-20.
Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells. 2012;30:55-60.
Lee S, Huh JY, Turner DM, Lee S, Robinson J, Stein JE, et al. Repurposing the cord blood bank for haplobanking of HLA-homozygous iPSCs and their usefulness to multiple populations. Stem Cells. 2018;36:1552-66.
Liedtke S, Korschgen L, Korn J, Duppers A, Kogler G. GMP-grade CD34+ selection from HLA-homozygous licensed cord blood units and short-term expansion under European ATMP regulations. Vox Sang. 2021;116:123-35.
Umekage M, Sato Y, Takasu N. Overview: an iPS cell stock at CiRA. Inflammation Regeneration. 2019;39:17.
Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13:859-66.
Ree IMC, Lopriore E. Updates in neonatal hematology: causes, risk factors, and management of anemia and thrombocytopenia. Hematol Oncol Clin North Am. 2019;33:521-32.
Stutchfield CJ, Jain A, Odd D, Williams C, Markham R. Foetal haemoglobin, blood transfusion, and retinopathy of prematurity in very preterm infants: a pilot prospective cohort study. Eye. 2017;31:1451-5.
Podraza W. A new approach to neonatal medical management that could transform the prevention of retinopathy of prematurity: theoretical considerations. Med Hypotheses. 2020;137:109541.
Bianchi M, Giannantonio C, Spartano S, Fioretti M, Landini A, Molisso A, et al. Allogeneic umbilical cord blood red cell concentrates: an innovative blood product for transfusion therapy of preterm infants. Neonatology. 2015;107:81-6.
Teofili L, Papacci P, Orlando N, Bianchi M, Molisso A, Purcaro V, et al. Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TrIP study. Br J Haematol. 2020;191:263-8.
Lopriore E, Huisman E, Zwaginga JJ, Snijder PM, Reiss IK, Stanworth S. Allogeneic cord blood transfusions for extremely preterm neonates: an extremely promising proof of concept. Br J Haematol. 2020;191:150-1.
Rosso L, Parazzi V, Damarco F, Righi I, Santambrogio L, Rebulla P, et al. Pleural tissue repair with cord blood platelet gel. Blood Transfus. 2014;12:235-42.
Gelmetti A, Greppi N, Guez S, Grassi F, Rebulla P, Tadini G, et al. Cord blood platelet gel for the treatment of inherited epidermolysis bullosa. Transfus Apheres Sci. 2018;57:370-3.
Giannaccare G, Carnevali A, Senni C, Logozzo L, Scorcia V. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther. 2020;9:235-48.
Samarkanova D, Rodríguez L, Vives J, Coll R, Tahull E, Azqueta C, et al. Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application. Blood Transfus. 2020;18:208-16.
Samarkanova D, Martin S, Bisbe L, Puig J, Calatayud-Pinuaga M, Rodriguez L, et al. Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Blood Transfus. 2020. https://doi.org/10.2450/2020.0130-20.